ACETAMINOPHEN AND IBUPROFEN
Post-LOEacetaminophen and ibuprofen (nsaid) tablets, 250 mg/ 125 mg
ANDAORALTABLET
Approved
Aug 2024
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ACETAMINOPHEN AND IBUPROFEN (acetaminophen and ibuprofen (nsaid) tablets, 250 mg/ 125 mg) by Dr. Reddy's Laboratories is cyclooxygenase inhibitors [moa]. First approved in 2024.
Drug data last refreshed 21h ago
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on ACETAMINOPHEN AND IBUPROFEN at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.